BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Immunomedics, Inc. 

300 American Road

Morris Plains  New Jersey  07950-2450  U.S.A.
Phone: 201-605-8200 Fax: 973-605-8282


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Immunomedics, Inc. (IMMU) Awarded Fast Track Designation By FDA For Sacituzumab Govitecan For Non-Small Cell Lung Cancer Therapy 5/15/2015 11:04:06 AM
Immunomedics, Inc. (IMMU) Awarded $1.2 Million Department Of Defense Grant For Development Of ARA-LAMP-Vax Peanut Allergy Vaccine 5/13/2015 7:49:11 AM
Immunomedics, Inc. (IMMU) Extends U.S. Patent Protection For Sacituzumab Govitecan To 2033 5/12/2015 7:41:34 AM
Immunomedics, Inc. (IMMU) Announces Third Quarter Fiscal 2015 Results And Clinical Program Developments 5/7/2015 8:04:34 AM
Immunomedics, Inc. (IMMU) Announces Conference Call And Webcast For Third Quarter Fiscal 2015 Financial Results 4/30/2015 8:27:52 AM
Patients With Advanced Breast, Lung, Esophageal, And Colorectal Cancers Respond To Immunomedics, Inc. (IMMU)' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments 4/20/2015 2:23:09 PM
Immunomedics, Inc. (IMMU) To Provide Update On Sacituzumab Govitecan For The Therapy Of Solid Cancers 4/6/2015 7:07:47 AM
Immunomedics, Inc. (IMMU) Presents Updated Results With Sacituzumab Govitecan in Lung Cancer 2/20/2015 7:26:10 AM
Immunomedics, Inc. (IMMU) Announces Completion Of Offering Of $85 Million Of 4.75% Convertible Senior Notes Due 2020 2/12/2015 7:29:14 AM
Immunomedics, Inc. (IMMU) Announces Pricing Of Offering of $85 Million Of 4.75% Convertible Senior Notes Due 2020 2/6/2015 7:38:09 AM
12345678910...